WHO position statement on the use of delamanid for multidrug-resistant tuberculosis : Expedited review of the phase III clinical trial data of delamanid added to an optimised background MDR-TB regimen / World Health Organization; Moja L. ; [a cura di] W. Health Organization, L. Moja. - [s.l] : World Health Organization, 2018 Jan.

WHO position statement on the use of delamanid for multidrug-resistant tuberculosis : Expedited review of the phase III clinical trial data of delamanid added to an optimised background MDR-TB regimen

L. Moja
2018

World Health Organization; Moja L.
English
Prima edizione
World Health Organization
gen-2018
9
Settore MED/42 - Igiene Generale e Applicata
Settore MED/17 - Malattie Infettive
Altro
Volume a diffusione internazionale
Ricerca applicata
Pubblicazione scientifica
http://www.who.int/tb/publications/2018/WHOPositionStatementDelamanidUse.pdf?ua=1
Aderisco
W. Health Organization, L. Moja
2
WHO position statement on the use of delamanid for multidrug-resistant tuberculosis : Expedited review of the phase III clinical trial data of delamanid added to an optimised background MDR-TB regimen / World Health Organization; Moja L. ; [a cura di] W. Health Organization, L. Moja. - [s.l] : World Health Organization, 2018 Jan.
reserved
284
Book (editor)
Prodotti della ricerca::06 - Curatela di volume
info:eu-repo/semantics/other
File in questo prodotto:
File Dimensione Formato  
WHOPositionStatementDelamanidUse.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 592.68 kB
Formato Adobe PDF
592.68 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/547465
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact